Formulation and Optimization of Cilnidipine Nanoparticle-loaded Mucoadhesive Buccal Tablets using Quality by Design Approach for Enhanced Systemic Bioavailability
Abstract
Cilnidipine, a calcium channel blocker used to treat hypertension, has poor oral bioavailability owing to extensive first-pass intestinal and hepatic metabolism. Buccal delivery offers an alternative route that bypasses hepatic first-pass metabolism and provides controlled systemic absorption. This study aimed to formulate and optimize a cilnidipine nanoparticle-loaded mucoadhesive buccal tablet using a Quality by Design (QbD) approach. Cilnidipine polymeric nanoparticles (polyvinylpyrrolidone K-30 with Pluronic F68), prepared by a solvent-evaporation method and characterized in our earlier work, were incorporated into a mucoadhesive matrix of hydroxypropyl methylcellulose (HPMC K4M and HPMC K15M) and Carbopol 934. Tablet hardness and cumulative drug release at 12 h were selected as the critical quality attributes and optimized using an Extreme Vertices Mixture Design (EVMD). Pre- and post-compression parameters, mucoadhesive strength, in vitro dissolution, swelling, release kinetics, and stability under ICH conditions were evaluated. All formulations showed acceptable weight uniformity, hardness, and friability. The optimized formulation (BTF9) achieved 92.2% cumulative drug release over 12 h. The release data best fitted the Higuchi model (R² = 0.994), and the Korsmeyer-Peppas exponent indicated Fickian diffusion. Accelerated stability testing showed no significant change in the key parameters over six months. Drug release and mucoadhesion were strongly influenced by polymer composition; the optimized polymer combination prevented burst release and sustained drug release while maintaining adequate mucoadhesion. The nanoparticle-loaded mucoadhesive buccal tablet is a promising candidate for improving the bioavailability of cilnidipine in the management of hypertension. This non-invasive, patient-friendly platform may reduce dosing frequency and improve adherence, and it provides a translational basis for future in vivo and clinical evaluation.